Another trial of the blocker durvalumab included 30 cases for MSI-H/dMMR and 3 cases of POLE mutant MSS CRC, with a median follow-up of 11.2 months (95% CI: 7.3–15.0) and an ORR of 42.4% (95% CI: 25.5–60.8) (27). Here, POLE is linked to colorectal carcinoma.